Literature DB >> 12701046

17Beta-estradiol and anti-estrogen ICI:compound 182,780 regulate expression of lipoprotein lipase and hormone-sensitive lipase in isolated subcutaneous abdominal adipocytes.

S L Palin1, P G McTernan, L A Anderson, D W Sturdee, A H Barnett, S Kumar.   

Abstract

We sought to investigate the influence of 17beta-estradiol (E(2)) on key enzymes of lipogenesis and lipolysis in subcutaneous (SC) abdominal adipocytes isolated from women. In addition, we wished to determine the influence of an anti-estrogen, ICI:compound 182,780 (anti-E), known to act via the estrogen receptor (ER), alone and in combination with E(2). Adipose tissue was obtained from 17 women undergoing elective surgery, with a mean age of 47 years (range, 34 to 62), mean weight of 65.4 kg (range, 58.1 to 75.0), and mean body mass index (BMI) of 25 kg/m(2) (range, 22 to 27). Isolated adipocytes were treated with varying doses of E(2), anti-E, or E(2) in combination with anti-E 10(-8) mol/L for 48 hours. Following treatment, proteins were extracted and the effects on lipogenesis and lipolysis were assessed, using Western blotting to determine the relative expression of the key enzymes of these processes, lipoprotein lipase (LPL; 56 kd), and hormone-sensitive lipase (HSL; 84 kd), respectively. Glycerol release into the medium was also measured as an index of lipolytic activity. The protein expression studies demonstrated that E(2) altered expression of LPL relative to control, with the highest dose significantly reducing LPL expression and the lower doses significantly increasing LPL expression (mean protein expression relative to control +/- SE): E(2) 10(-12) mol/L, 1.79 +/- 0.16 (P <.001); E(2) 10(-7) mol/L, 0.56 +/- 0.08 (P <.05). In contrast, HSL expression was increased relative to control at the higher doses of E(2) but was not significantly altered relative to control at the lower doses: E(2) 10(-12) mol/L, 1.02 +/- 0.14 (P >.05); E(2) 10(-7) mol/L, 1.55 +/- 0.17 (P <.01). Anti-E 10(-8) mol/L alone reduced LPL protein expression relative to control (P <.05) and increased HSL protein expression relative to control (P >.05). In combination with E(2) 10(-7) mol/L, anti-E 10(-8) mol/L did not abrogate the inhibitory effect on LPL expression relative to control (P <.05). Furthermore, E(2) 10(-7) mol/Lin combination with anti-E 10(-8) mol/L, displayed a stimulatory effect on HSL expression relative to control (P <.01). Glycerol release studies following the higher doses of E(2), and also following E(2) 10(-7) mol/L in combination with anti-E 10(-8) mol/L, provided support for the HSL protein expression studies. We conclude that the highest concentration of E(2) (10(-7) mol/L) significantly reduced LPL expression relative to control, while the lower concentrations significantly increased LPL expression relative to control. The highest concentration of E(2) also significantly increased both HSL expression and glycerol release relative to control. The effects of anti-E suggest that the in vitro effects of E(2) on lipogenesis and lipolysis occur, at least in part, through a receptor-mediated pathway. In addition, as recently observed in other tissues, ICI:compound 182,780 does not appear to behave as a pure anti-estrogen in isolated human adipocytes. Copyright 2003 Elsevier, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12701046     DOI: 10.1053/meta.2003.50088

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  19 in total

1.  Estrogen sulfotransferase inhibits adipocyte differentiation.

Authors:  Taira Wada; Chibueze A Ihunnah; Jie Gao; Xiaojuan Chai; Su Zeng; Brian J Philips; J Peter Rubin; Kacey G Marra; Wen Xie
Journal:  Mol Endocrinol       Date:  2011-08-04

Review 2.  Estrogens and Body Weight Regulation in Men.

Authors:  Katya B Rubinow
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

3.  Ovarian cycle-specific regulation of adipose tissue lipid storage by testosterone in female nonhuman primates.

Authors:  Oleg Varlamov; Michael P Chu; Whitney K McGee; Judy L Cameron; Robert W O'Rourke; Kevin A Meyer; Cecily V Bishop; Richard L Stouffer; Charles T Roberts
Journal:  Endocrinology       Date:  2013-09-05       Impact factor: 4.736

4.  Gender-specific expression and mechanism of regulation of estrogen sulfotransferase in adipose tissues of the mouse.

Authors:  Victor K Khor; Ming Han Tong; Yueming Qian; Wen-Chao Song
Journal:  Endocrinology       Date:  2008-07-31       Impact factor: 4.736

Review 5.  G protein-coupled estrogen receptor in energy homeostasis and obesity pathogenesis.

Authors:  Haifei Shi; Shiva Priya Dharshan Senthil Kumar; Xian Liu
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

6.  Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women.

Authors:  F A Syed; M J Oursler; T E Hefferanm; J M Peterson; B L Riggs; S Khosla
Journal:  Osteoporos Int       Date:  2008-02-15       Impact factor: 4.507

7.  Role of nuclear receptors in lipid dysfunction and obesity-related diseases.

Authors:  Hollie I Swanson; Taira Wada; Wen Xie; Barbara Renga; Angela Zampella; Eleonora Distrutti; Stefano Fiorucci; Bo Kong; Ann M Thomas; Grace L Guo; Ramesh Narayanan; Muralimohan Yepuru; James T Dalton; John Y L Chiang
Journal:  Drug Metab Dispos       Date:  2012-10-04       Impact factor: 3.922

8.  Estrogen-enhanced gene expression of lipoprotein lipase in heart is antagonized by progesterone.

Authors:  Dianxin Liu; Anne Deschamps; Kenneth S Korach; Elizabeth Murphy
Journal:  Endocrinology       Date:  2007-11-01       Impact factor: 4.736

Review 9.  Obesity: a neuroimmunometabolic perspective.

Authors:  Chelsea M Larabee; Oliver C Neely; Ana I Domingos
Journal:  Nat Rev Endocrinol       Date:  2019-11-27       Impact factor: 43.330

10.  Fatty Acid Oxidation and Cardiovascular Risk during Menopause: A Mitochondrial Connection?

Authors:  Paulo J Oliveira; Rui A Carvalho; Piero Portincasa; Leonilde Bonfrate; Vilma A Sardao
Journal:  J Lipids       Date:  2012-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.